Use of beta-glucans against biological warfare weapons and pathogens including anthrax
The present invention provides a means to broadly protect the military and the public from injury from biological warfare weapons, particularly infective agents such as anthrax. Beta (1,3)-glucans, particularly whole glucan particles, PGG-Glucan, and microparticulate glucan, provide general immune enhancement, thereby increasing the body's ability to defend against a wide variety of biological threats. Beta (1,3)-glucans have been shown to increase the resistance to infection by anthrax and other infectious organisms when administered before and after infection. The anti-infective mechanism of β(1,3)-glucan appears to involve stimulation of the innate immune system through increased cytokine release and CR3 receptor activation. Beta (1,3)-glucan is pharmaceutically stable, relatively compact, and can also be used without significant side effects. Beta (1,3)-glucan can also enhance the effectiveness of other medical countermeasures such as antibiotics, vaccines, and immune antibodies.
1. A method of treating humans or animals at imminent risk of exposure and/or after exposure to anthrax consisting essentially of administering an effective amount of underivatized β(1,3)-Glucan to the human or animal.
2. The method of treating humans or animals at imminent risk of exposure and/or after exposure to anthrax of claim 1 , wherein said underivatized β(1-3)-Glucan comprises PGG glucan, whole glucan particles or a combination of PGG and whole glucan particles.
3. The method of treating humans or animals at imminent risk of exposure and/or after exposure to anthrax of claim 2 , wherein greater than 0.01 mg/Kg of whole glucan particles is administered daily.
4. The method of treating humans or animals at imminent risk of exposure and/or after exposure to anthrax of claim 2 , wherein a combination of about 0.1-100 mg/Kg of PGG glucan and about 0.1-500 mg/Kg of whole glucan particles is administered daily.
5. The method of treating humans or animals at imminent risk of exposure and/or after exposure to anthrax of claim 3 , wherein about 2.5 mg/Kg of PGG glucan is administered daily or about 10 mg/Kg of whole glucan particles is administered daily.
6. The method of treating humans or animals at imminent risk of exposure and/or after exposure to anthrax of claim 4 , wherein a combination of about 1-10 mg/Kg of PGG glucan and about 2-20 mg/Kg of whole glucan particles is administered daily.
7. The method of treating humans or animals at imminent risk of exposure and/or after exposure to anthrax of claim 2 , wherein said underivatized β(1-3)-Glucan comprises PGG glucan.
8. The method of treating humans or animals at imminent risk of exposure and/or after exposure to anthrax of claim 2 , wherein said underivatized β(1-3)-Glucan comprises whole glucan particles.
9. The method of treating humans or animals at imminent risk of exposure and/or after exposure to anthrax of claim 2 , wherein said underivatized β(1-3)-Glucan comprises a combination of PGG glucan and whole glucan particles.
10. The method of treating humans or animals at imminent risk of exposure and/or after exposure to anthrax of claim 1 , wherein the underivatized β(1,3)-Glucan is administered orally, topically, subcutaneously, intramuscularly, transdermally, intradermally, intravenously, or through the gastrointestinal tract.
11. The method of treating humans or animals at imminent risk of exposure and/or after exposure to anthrax of claim 10 , wherein the underivatized β(1,3)-Glucan is administered orally.